Raul C. Urtasun

Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside.

M. Parliament, A. McEwan, J D Chapman, 1996, The British journal of cancer. Supplement.

Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma.

E. Bruera, R. Urtasun, L. Wood, 1998, British Journal of Cancer.

Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme.

P. Okunieff, A. Taghian, N. Bleehen, 1992, International journal of radiation oncology, biology, physics.

Does improved depth dose characteristics and treatment planning correlate with a gain in therapeutic results? Evidence from past clinical experience using conventional radiation sources.

R. Urtasun, R C Urtasun, Raul C. Urtasun, 1992, International journal of radiation oncology, biology, physics.

Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons.

J. Allalunis-Turner, J. Miyakoshi, K. Petruk, 1990, Cancer research.

Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12).

T. Kinsella, T. Wasserman, J. Delrowe, 1993, International journal of radiation oncology, biology, physics.

Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.

C. Coleman, S. Hancock, T. Wasserman, 1986, International journal of radiation oncology, biology, physics.

Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.

C. Coleman, S. Hancock, J. Harris, 1984, International journal of radiation oncology, biology, physics.